Methyl morpholine oxide → 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2,3-dihydroxy-propoxy)-amide
反応式
[CH2:1]([O:4][NH:5][C:6]([C:8]1[C:17]([NH:18][C:19]2[CH:24]=[CH:23][C:22]([Br:25])=[CH:21][C:20]=2[Cl:26])=[C:16]([F:27])[C:11]2[N:12]=[CH:13][N:14]([CH3:15])[C:10]=2[CH:9]=1)=[O:7])[CH:2]=[CH2:3].[O:28]1CCCC1.[OH2:33].C[N+]1([O-])CCOCC1.OS([O-])=O.[Na+]>C(OCC)(=O)C.O=[Os](=O)(=O)=O>[OH:33][CH:2]([CH2:3][OH:28])[CH2:1][O:4][NH:5][C:6]([C:8]1[C:17]([NH:18][C:19]2[CH:24]=[CH:23][C:22]([Br:25])=[CH:21][C:20]=2[Cl:26])=[C:16]([F:27])[C:11]2[N:12]=[CH:13][N:14]([CH3:15])[C:10]=2[CH:9]=1)=[O:7]参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
To a solution of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid allyloxy-amide 29tt (20 mg, 0.04 mmol) in 0.50 mL 4:1 tetrahydrofuran/water is added OsO4 (41 μL, 0.054 M solution in t-BuOH, 0.002 mmol) followed by NMO (7 mg, 0.06 mmol). The solution is stirred at room temperature for eight hours after which time HPLC analysis showed complete conversion to product. The solution is then stirred with saturated NaHSO3 and diluted with ethyl acetate. The organic phase is dried (Na2SO4). Purification by FCC (DCM->20:1 DCM/MeOH) provided 16 mg desired product as an off-white solid. MS ESI (+) m/z 487, 489 (M+, Br pattern) detected.
後処理
- dry with materialThe organic phase is dried (Na2SO4)
- customPurification by FCC (DCM->20:1 DCM/MeOH)
出典と根拠
- ORDレコード
- ord-839e7e3adba846abae212c19253f9df4
- 出典データセット
- uspto-grants-2012_06
- 特許番号
- US08193231B2
反応ノート
読み込み中…